Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: An open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients

Journal of Parkinson's Disease

Volumn 5, Issue 1, 2015, Pages 165-174

  Slevin, John T ^a   Fernandez, Hubert H ^b   Zadikoff, Cindy ^c   Hall, Coleen ^d   Eaton, Susan ^d   Dubow, Jordan ^d   Chatamra, Krai ^d   Benesh, Janet ^d  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d ABBVIE INC   (United States)

Author keywords

clinical trial; levodopa carbidopa intestinal gel; motor fluctuations; Parkinson's disease; percutaneous endoscopic gastrostomy

Indexed keywords

ANTIBIOTIC AGENT; ANTIPARKINSON AGENT; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; GEL;

ABDOMINAL PAIN; ADULT; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; ASPIRATION PNEUMONIA; ASTHENIA; AUDITORY HALLUCINATION; CHOLECYSTITIS; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DELUSION; DIGESTIVE SYSTEM INJURY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; EUROQUAL QUALITY OF LIFE 5 DIMENSIONS; FAINTNESS; FALLING; FEMALE; GASTROENTERITIS; GASTROINTESTINAL HEMORRHAGE; GASTROJEJUNOSTOMY; GEL; HALLUCINATION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; HYPOXIA; INFUSION PUMP; INJECTION SITE ERYTHEMA; INSOMNIA; INTESTINE ISCHEMIA; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; KIDNEY TUMOR; LUMBAR SPINAL STENOSIS; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; MUSCLE RIGIDITY; NAUSEA; ORTHOSTATIC HYPOTENSION; PARANOIA; PARKINSON DISEASE; PARKINSON DISEASE QUESTIONNAIRE; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PERIPHERAL NEUROPATHY; PERITONITIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POLYNEUROPATHY; PROSTATE HYPERTROPHY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEBORRHEIC KERATOSIS; SEPSIS; SURGICAL INFECTION; URETHRA STENOSIS; URINARY TRACT INFECTION; URINE RETENTION; WOUND INFECTION; ZARIT BURDEN INTERVIEW; AGE; AGED; CLINICAL TRIAL; LONGITUDINAL STUDY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; THERAPEUTIC USE;

AGE FACTORS; AGED; ANTIPARKINSON AGENTS; CARBIDOPA; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; FEMALE; GELS; HUMANS; LEVODOPA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX;

EID: 84923121193     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-140456     Document Type: Article

References (23)

1. Lundqvist C (2007) Continuous levodopa for advanced Parkinson's disease. Neuropsychiatr Dis Treat, 3, 335-348.
2. Chase TN (1998) The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs, 55, 1-9.
3. Antonini A, Chaudhuri KR, Martinez-Martin P, & Odin P (2010) Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease. CNS Drugs, 24, 119-129.
4. Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL, & Chase TN (1989) Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol, 25, 523-526.
5. Obeso JA, Olanow CW, & Nutt JG (2000) Levodopa motor complications in Parkinson's disease. Trends Neurosci, 23, S2-S7.
6. Chapuis S, Ouchchane L, Metz O, Gerbaud L, & Durif F (2005) Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord, 20, 224-230.
7. Ahlskog JE, & Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord, 16, 448-458.
8. Hardoff R, Sula M, Tamir A, Soil A, Front A, Badarna S, Honigman S, & Giladi N (2001) Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord, 16, 1041-1047.
9. Nyholm D, Odin P, Johansson A, Chatamra K, Locke C, Dutta S, & Othman AA (2013) Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients. AAPS J, 15, 316-323.
10. Müller T, van Laar T, Cornblath DR, Odin P, Klostermann F, Grandas FJ, Ebersbach G, Urban PP, Valldeoriola F, & Antonini A (2013) Peripheral neuropathy in Parkinson's disease: Levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord, 19, 501-507.
11. Toth C, Breithaupt K, Ge S, Duan Y, Terris JM, Thiessen A, Wiebe S, Zochodne DW, & Suchowersky O (2010) Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol, 68, 28-36.
12. Rajabally YA, & Martey J (2011) Neuropathy in Parkinson disease: Prevalence and determinants. Neurology, 77, 1947-1950.
13. Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, Dal Fante M, Lopiano L, & Pezzoli G (2007) Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord, 22, 1145-1149.
14. Mancini F, Comi C, Oggioni GD, Pacchetti C, Calandrella D, Coletti Moja M, Riboldazzi G, Tunesi S, Dal Fante M, Manfredi L, Lacerenza M, Cantello R, & Antonini A (2014) Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens. Parkinsonism Relat Disord, 20, 27-31.
15. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, & Antonini A (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: A randomised, controlled, double-blind, double-dummy study. Lancet Neurol, 13, 141-149.
16. Fernandez HH, Standaert DG, Hauser RA, Lang A, Fung VSC, Klostermann F, Lew M, Odin P, Steiger M, Yakupov EZ, Choudinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh J, Espay AJ (2014) Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: Final 12-month, open-label results. Mov Disord, doi: 10.1002/mds.26123
17. MedDRA Maintenance and Support Services Organization. Medical Dictionary for Regulatory Activities (MedDRA), Version 14.0 2011. Available from: https://meddramsso.com
18. Martinez-Martin P, Gil-Nagel A, Gracia LM, Gomez JB, Martinez-Sarries J, & Bermejo F (1994) Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord, 9, 76-83.
19. Peto V, Jenkinson C, & Fitzpatrick R (1998) PDQ-39: A review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol, 245(Suppl 1), S10-S14.
20. Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O'Brien CF, Molho ES, & Factor SA (2000) A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol, 23, 75-81.
21. Folstein MF, Folstein SE, & McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 12, 189-198.
22. Chovancova Z, Kanovsky P, Dufek J, Nevrly M, & Otruba P (2009) Peripheral nerve involvement and severity of motor disorder in Parkinson's disease: A correlational study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 153, 59-62.
23. Ceravolo R, Cossu G, Bandettini di Poggio M, Santoro L, Barone P, Zibetti M, Frosini D, Nicoletti V, Manganelli F, Iodice R, Picillo M, Merola A, Lopiano L, Paribello A, Manca D, Melis M, Marchese R, Borelli P, Mereu A, Contu P, Abbruzzese G, & Bonuccelli U (2013) Neuropathy and levodopa in Parkinson's disease: Evidence from a multicenter study. Mov Disord, 28, 1391-1397.